Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4548 On Other Exchanges
Symbol
Exchange
4548 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

seikagaku corp (4548) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEIKAGAKU CORP (4548)

Related News

No related news articles were found.

seikagaku corp (4548) Related Businessweek News

No Related Businessweek News Found

seikagaku corp (4548) Details

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates through, Pharmaceuticals and LAL segments. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, SUPARTZ, ARTZAL, etc.; injection medical device for treating osteoarthritis pain of the knee under the brand name of Gel-One; ophthalmic surgical aids under the brands OPEGAN and OPEGAN Hi; and surgical aid for endoscopic mucosal resection under the brand name of MucoUp. The company also provides bulk products comprising sodium hyaluronate, which is used as a raw material for the manufacturers of pharmaceuticals; and sodium chondroitin sulfate that is used as a raw material in pharmaceuticals, ophthalmic products, and drinks for nutritional fortification. In addition, it develops endotoxin-detecting reagents for use in quality control in the manufacturing process and release test of pharmaceuticals and medical devices, as well as in quality management of fluids for hemodialysis under the Pyrochrome, ENDOSPECY, TOXICOLOR, etc. brands. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 that is in Phase III clinical trials for lumbar disc herniation; SI-657, an additional indication of ARTZ for enthesopathy; SI-614, a therapeutic drug for dry eyes; and SI-613, a treatment for knee osteoarthritis. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

649 Employees
Last Reported Date: 06/19/15
Founded in 1947

seikagaku corp (4548) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seikagaku corp (4548) Key Developments

Seikagaku Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2015; Provides Dividend Guidance for the Year Ending March 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2016

Seikagaku Corporation reported consolidated earnings results for the nine months ended December 31, 2015. The company reported net sales of JPY 23,437 million compared with JPY 22,075 million for the same period last year. Operating income was JPY 2,743 million compared with JPY 2,273 million for the same period last year. This result reflects the sales increase, despite the impact of depreciation of the No. 5 Production Building at the Takahagi Plant and higher expenses related to U.S. operations, including the overseas subsidiary. Ordinary income was JPY 4,006 million compared with JPY 3,787 million for the same period last year as a result of factors including a decrease in gain on valuation of foreign currency-denominated assets due to a decrease in the magnitude of yen depreciation compared to the first nine months of the previous year (fiscal 2014). Net income attributable to owners of parent was JPY 3,017 million or JPY 53.11 per share compared with JPY 3,042 million or JPY 53.56 per share for the same period last year, reflecting the expiration of a temporary tax rate reducing factors applied in fiscal 2014. The change in increase of sales was attributable to the impact of yen depreciation and an increase in overseas pharmaceuticals sales volume. For the fiscal year ending March 31, 2016, the company expects year-end dividend of JPY 13.00 per share against JPY 13.00 per share paid for the same period a year ago. The company provided consolidated earnings guidance for the fiscal year ending March 31, 2016. The company expects net sales of JPY 30,650 million, operating income of JPY 2,400 million, ordinary income of JPY 3,800 million and net income of JPY 2,900 million or JPY 51.05 per share.

Seikagaku Corp. to Report Q3, 2016 Results on Feb 02, 2016

Seikagaku Corp. announced that they will report Q3, 2016 results at 3:00 PM, Tokyo Standard Time on Feb 02, 2016

Seikagaku Corp. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2016; Announces Dividend for the Second Quarter Ended September 30, 2015, Payable on December 2, 2015; Provides Year-End Dividend Guidance for the Year Ending March 31, 2016

Seikagaku Corp. reported consolidated earnings results for the six months ended September 30, 2015. For the period, the company reported net sales of JPY 15,954 million compared to JPY 14,247 million a year ago. Operating income was JPY 2,050 million compared to JPY 1,564 million a year ago. Ordinary income was JPY 2,575 million compared to JPY 2,109 million a year ago. Net income attributable to owners of parent was JPY 1,941 million compared to JPY 1,687 million a year ago. Net income per share was JPY 34.18 compared to JPY 29.71 a year ago. The sales change is attributable to an increase in overseas pharmaceuticals sales volume and the impact of yen depreciation. Operating income rose 31.1% year on year, reflecting the sales increase, despite depreciation of the No. 5 Production Building at the Takahagi Plant and higher R&D expenses resulting from progress on development themes such as SI-6603, indicated for treatment of lumbar disc herniation in the U.S. Ordinary income rose 22.1% as a result of factors including a decrease in gain on valuation of foreign currency-denominated assets because of a decrease in the magnitude of yen depreciation. Net income attributable to owners of the parent rose 15.0%, reflecting the expiration of a temporary tax rate reduction applied in fiscal 2014. The company provided consolidated earnings guidance for the year ending March 31, 2016. For the year, the company expects net sales of JPY 30,650 million, operating income of JPY 2,400 million, ordinary income of JPY 3,800 million, net income attributable to owners of parent of JPY 2,900 million or JPY 51.05 per share. For the second quarter ended September 30, 2015, the company announced dividend of JPY 13.00 per share compared to JPY 13.00 per share a year ago. Scheduled date to commence dividend payment is December 2, 2015. The company provided year-end dividend guidance for the year ending March 31, 2016. The company expects year-end dividend of JPY 13.00 per share for the year ending March 31, 2016 compared to JPY 13.00 per share for the year ended March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4548:JP ¥1,289.00 JPY -56.00

4548 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Zimmer Biomet Holdings Inc $91.90 USD -0.13
View Industry Companies
 

Industry Analysis

4548

Industry Average

Valuation 4548 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SEIKAGAKU CORP, please visit www.seikagaku.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.